Media Coverage

Quest Diagnostics and the bioinformatics company Hc1 have unveiled Quest Lab Stewardship, a service that uses machine learning to harmonize laboratory testing across health care systems in an effort to improve lab test utilization.[CR-LF][CR-LF]Quest Lab Stewardship “integrates in real-time with enterprise systems and leverages Hc1’s machine-learning capabilities to ingest, organize, and normalize lab data, alleviating the time and effort of manual data gathering and analysis,” according to a press announcement from Quest. “It also provides a framework for lab directors and hospital administrators to consult with medical staff to identify areas of concern and implement compendium updates and order prompting based on selected clinical guidelines.”

If you've been prescribed pain pills and think doctors are avoiding you as a new patient, you just might be right. [CR-LF][CR-LF]A large percentage of primary-care doctors (81%) say they're hesitant to accept new patients who've been prescribed pain meds, a newly released survey shows. Even more (83%) say the opioid crisis makes it harder to treat pain patients.[CR-LF]The new report, Drug Misuse in America 2019: Physicians Perspectives and Diagnostics Insights on the Evolving Drug Crisis, shows findings indicating that the opioid crisis continues to have a major impact on physicians and people in pain.

If you've been prescribed pain pills and think doctors are avoiding you as a new patient, you just might be right. [CR-LF][CR-LF]A large percentage of primary-care doctors (81%) say they're hesitant to accept new patients who've been prescribed pain meds, a newly released survey shows. Even more (83%) say the opioid crisis makes it harder to treat pain patients.[CR-LF]The new report, Drug Misuse in America 2019: Physicians Perspectives and Diagnostics Insights on the Evolving Drug Crisis, shows findings indicating that the opioid crisis continues to have a major impact on physicians and people in pain.

While reporting financial results for the third quarter on Tuesday, Quest Diagnostics Inc. (DGX) raised its earnings and adjusted earnings guidance for the full-year 2019. For fiscal 2019, the company now projects earnings in a range of $5.48 to $5.53 per share and adjusted earnings in a range of $6.45 to $6.50 per share on net revenues of about $7.72 billion.

Almost three-quarters of primary care physicians believe that their patients will take their controlled medications as prescribed, but more than half of drug-monitoring lab tests show signs of misuse, according to a new report from Quest Diagnostics.